Changes in Valganciclovir Use Among Infants with Congenital Cytomegalovirus Diagnosis in the United States, 2009-2015 and 2016-2019 - 22/06/22
Doi : 10.1016/j.jpeds.2022.03.042
Jessica Leung, MPH 1, ⁎ 
, Scott D. Grosse, PhD 2, Kai Hong, PhD, MS 1, Megan H. Pesch, MD, MS 3, Tatiana M. Lanzieri, MD, MPH 1
, Scott D. Grosse, PhD 2, Kai Hong, PhD, MS 1, Megan H. Pesch, MD, MS 3, Tatiana M. Lanzieri, MD, MPH 1 1 National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA
2 National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA
3 Division of Developmental and Behavioral Pediatrics, Department of Pediatrics, University of Michigan, Ann Arbor, MI
∗Reprint requests: Jessica Leung, MPH, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, MS H24-5, Atlanta, GA 30333.Centers for Disease Control and Prevention1600 Clifton Rd NE, MS H24-5AtlantaGA30333
Abstract |
From 2009-2015 to 2016-2019, the proportion of infants in the US with congenital cytomegalovirus treated with valganciclovir roughly doubled for infants enrolled with employer-sponsored insurance (from 16% to 29%) and Medicaid (from 16% to 36%). The proportion treated with valganciclovir increased for all congenital cytomegalovirus disease severity groups.
Le texte complet de cet article est disponible en PDF.Keywords : CMV, congenital cytomegalovirus, antiviral, valganciclovir, administrative data
Abbreviations : AAP, cCMV, CMS, CNS, ESI, RCT, SNHL
Plan
| M.P. serves on the board of Directors for the National CMV Foundation (unpaid). The National CMV Foundation played no role in the conception, analysis, data interpretation, or writing of this manuscript. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention, US Department of Health and Human Services. The other authors declare no conflicts of interest. |
© 2022
Publié par Elsevier Masson SAS.
Vol 246
P. 274 - juillet 2022 Retour au numéro
Article précédent
- Acute Genital Ulceration After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination and Infection
- Tina Hsu, Jacquelyn R. Sink, Veronica I. Alaniz, Lida Zheng, Anthony J. Mancini
- Pincer Nails Upon Convalescence from Kawasaki Disease
- Osamu Matsumura, Yasuo Nakagishi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?